You need Flash player 8+ and JavaScript enabled to view this video.
You need Flash player 8+ and JavaScript enabled to view this video.
You need Flash player 8+ and JavaScript enabled to view this video.
News
FDA approves faricimab for treatment of wet AMD and DME
Faricimab will be the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, involved in retinal diseases and ... Read More >
(English) Novartis Provides Update on Use and Safety of Beovu in Patients With Wet AMD
(English) After the American Society of Retinal Specialists (ASRS) shared a note with its membership warning of vision-threatening cases of occlusive retinal vasculitis of wet AMD drug Beovu, Novartis... Read More >
(English) Beovu Approved for Wet AMD in European Union
(English) Following the Euopean Medicines Agency (EMA) human medicine’s committee recommendation in December, Beovu (brolucizumab) received formal approval by the European Commission … Sour... Read More >
(English) AMD Incidence to Rise by 75% and Affect 77 million Europeans by 2050
(English) In latest calculations, researchers pooled data from 22 prevalence studies involving 55,323 people, aged, on average, between 60 and 81, and from four incidence studies across Europe … ... Read More >
(English) Opthea OPT-302 Combo Outshines Lucentis Alone
(English) At EURETINA 2019 Congress, the Australia based company Ophthea reported data that OPT-302 reduced areas of neovascularization by 38% more and decreased scarring by 39% more, compared to Luce... Read More >
(English) Positive phase 2 trial results of anti-VEGF abicipar pegol for treating wet AMD
(English) Analysis of data from a Phase 2 study of abicipar pegol (Anti-VEGF DARPin®) in neovascular, or “wet,” age-related macular degeneration (AMD) showed positive results, leading to the deci... Read More >
